304 related articles for article (PubMed ID: 36808602)
41. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA; Thaçi D; Deleuran M; Blauvelt A; Bissonnette R; de Bruin-Weller M; Hide M; Sher L; Hussain I; Chen Z; Khokhar FA; Beazley B; Ruddy M; Patel N; Graham NMH; Ardeleanu M; Shumel B
Am J Clin Dermatol; 2020 Aug; 21(4):567-577. PubMed ID: 32557382
[TBL] [Abstract][Full Text] [Related]
42. Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial.
Siegfried EC; Bieber T; Simpson EL; Paller AS; Beck LA; Boguniewicz M; Schneider LC; Khokhar FA; Chen Z; Prescilla R; Mina-Osorio P; Bansal A
Am J Clin Dermatol; 2021 Mar; 22(2):243-255. PubMed ID: 33655423
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.
Paller AS; Siegfried EC; Thaçi D; Wollenberg A; Cork MJ; Arkwright PD; Gooderham M; Beck LA; Boguniewicz M; Sher L; Weisman J; O'Malley JT; Patel N; Hardin M; Graham NMH; Ruddy M; Sun X; Davis JD; Kamal MA; Khokhar FA; Weinreich DM; Yancopoulos GD; Beazley B; Bansal A; Shumel B
J Am Acad Dermatol; 2020 Nov; 83(5):1282-1293. PubMed ID: 32574587
[TBL] [Abstract][Full Text] [Related]
44. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
45. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a critical appraisal.
Thomson J; Wernham AGH; Williams HC
Br J Dermatol; 2018 Apr; 178(4):897-902. PubMed ID: 29315479
[TBL] [Abstract][Full Text] [Related]
46. Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis.
Paller AS; Siegfried EC; Cork MJ; Arkwright PD; Eichenfield LF; Ramien M; Khokhar FA; Chen Z; Zhang A; Cyr SL
Paediatr Drugs; 2024 Mar; 26(2):163-173. PubMed ID: 38267692
[TBL] [Abstract][Full Text] [Related]
47. Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study.
Merola JF; Chiou AS; During E; Costanzo A; Foley P; Alfalasi A; Gogate S; Pinter A; Dodiuk-Gad R; Simon D; Tauber M; Weller R; Pereyra-Rodriguez JJ; Ardeleanu M; Wu J; Ozturk ZE
Br J Dermatol; 2023 Nov; 189(6):685-694. PubMed ID: 37562034
[TBL] [Abstract][Full Text] [Related]
48. Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis.
Silverberg JI; Simpson EL; Boguniewicz M; De Bruin-Weller MS; Foley P; Kataoka Y; Bégo-Le-Bagousse G; Chen Z; Shumel B; Chao J; Rossi AB
Acta Derm Venereol; 2021 Nov; 101(11):adv00585. PubMed ID: 34618162
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
Guttman-Yassky E; Blauvelt A; Eichenfield LF; Paller AS; Armstrong AW; Drew J; Gopalan R; Simpson EL
JAMA Dermatol; 2020 Apr; 156(4):411-420. PubMed ID: 32101256
[TBL] [Abstract][Full Text] [Related]
50. Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment.
Armstrong A; Blauvelt A; Simpson EL; Smith CH; Herranz P; Kataoka Y; Seo SJ; Ferrucci SM; Chao J; Chen Z; Rossi AB; Shumel B; Tomondy P
Dermatol Ther (Heidelb); 2022 Jan; 12(1):195-202. PubMed ID: 34897582
[TBL] [Abstract][Full Text] [Related]
51. The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study.
Zhao Y; Wu L; Lu Q; Gao X; Zhu X; Yao X; Li L; Li W; Ding Y; Song Z; Liu L; Dang N; Zhang C; Liu X; Gu J; Wang J; Geng S; Liu Q; Guo Y; Dong L; Su H; Bai L; O'Malley JT; Luo J; Laws E; Mannent L; Ruddy M; Amin N; Bansal A; Ota T; Wang M; Zhang J
Br J Dermatol; 2022 Apr; 186(4):633-641. PubMed ID: 34358343
[TBL] [Abstract][Full Text] [Related]
52. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.
Cork MJ; Thaçi D; Eichenfield LF; Arkwright PD; Hultsch T; Davis JD; Zhang Y; Zhu X; Chen Z; Li M; Ardeleanu M; Teper A; Akinlade B; Gadkari A; Eckert L; Kamal MA; Ruddy M; Graham NMH; Pirozzi G; Stahl N; DiCioccio AT; Bansal A
Br J Dermatol; 2020 Jan; 182(1):85-96. PubMed ID: 31595499
[TBL] [Abstract][Full Text] [Related]
53. Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial.
Cork MJ; Lockshin B; Pinter A; Chen Z; Shumel B; Prescilla R
Acta Derm Venereol; 2024 Feb; 104():adv13467. PubMed ID: 38348724
[TBL] [Abstract][Full Text] [Related]
54. Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis-A pooled analysis of trial data.
Paller AS; Beck LA; Blauvelt A; Siegfried EC; Cork MJ; Wollenberg A; Chen Z; Khokhar FA; Vakil J; Zhang A; Bansal A; Cyr SL
Pediatr Dermatol; 2022 Mar; 39(2):187-196. PubMed ID: 35083774
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics, pharmacodynamics, and exposure-efficacy of dupilumab in adults with atopic dermatitis.
Kamal MA; Davis JD; Kovalenko P; Srinivasan K; Simpson EL; Nakahara T; Sugaya M; Igarashi A; Ardeleanu M; Xu C; Arima K
Clin Transl Sci; 2022 Oct; 15(10):2342-2354. PubMed ID: 35986664
[TBL] [Abstract][Full Text] [Related]
56. Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial.
Simpson EL; Silverberg JI; Worm M; Honari G; Masuda K; Syguła E; Schuttelaar MLA; Mortensen E; Laws E; Akinlade B; Patel N; Maloney J; Paleczny H; Delevry D; Xiao J; Dubost-Brama A; Bansal A
J Am Acad Dermatol; 2024 Jun; 90(6):1190-1199. PubMed ID: 38296199
[TBL] [Abstract][Full Text] [Related]
57. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Blauvelt A; Teixeira HD; Simpson EL; Costanzo A; De Bruin-Weller M; Barbarot S; Prajapati VH; Lio P; Hu X; Wu T; Liu J; Ladizinski B; Chu AD; Eyerich K
JAMA Dermatol; 2021 Sep; 157(9):1047-1055. PubMed ID: 34347860
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).
Simpson EL; Gooderham M; Wollenberg A; Weidinger S; Armstrong A; Soung J; Ferrucci S; Lima RG; Witte MM; Xu W; ElMaraghy H; Natalie CR; Pierce E; Blauvelt A;
JAMA Dermatol; 2023 Feb; 159(2):182-191. PubMed ID: 36630140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
